StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Kymriah (tisagenlecleucel by Quarter

Kymriah (tisagenlecleucel — Hematologic CAR-T Cell Therapy) ($M)

QuarterlyAnnual

Novartis Kymriah (tisagenlecleucel: $82M in Q3 2026, down 15.5% from a year earlier.

Latest, Q3 2026
82
Period ended Sep 30, 2026
Change on a year earlier
-15.5%
97 in Q3 2025
History
35 quarters
Since Q4 2017
Sources
27
Documents cited below

Where the Q3 2026 figure comes from

“|| Kymriah | 82 | 97 | – 15 | – 15”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKymriah (tisagenlecleucel — Hematologic CAR-T Cell Therapy) ($M)Year on yearSource
Q3 2026Sep 30, 202682-15.5%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 202688-11.1%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 202681-19.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202585-21.3%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 202597-4.9%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 202599-12.4%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025100-16.7%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024108-10.0%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024102-17.7%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024113-12.4%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024120-11.1%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023120-13.7%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023124-7.5%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023129-5.1%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023135+6.3%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022139-2.8%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up kymriah (tisagenlecleucel

Cite this data

StockData. (2026). Novartis Kymriah (tisagenlecleucel ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kymriah

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.